NAB-Sure™ RUO Kit:
Quantify Neutralizing Antibodies with finger prick blood collection
NAB-Sure™ SARS-CoV-2 Neutralizing Antibody Test kit offers the world’s first quantitative NAb assay for SARS-CoV-2 that only requires dried blood spot (DBS) collection.
More information for researchers and labs coming soon!
Ultrasensitive immunoassays enabling biomarker discovery, early detection, and home collection are a driving goal for researchers and clinicians advancing the field of proteomics.
Spear Bio’s immunoassay technology developed by Harvard University scientists enables ultrasensitive detection from small sample volumes and fits into existing workflows for sample collection, processing, and detection.
Spear Bio is ushering in the next generation of detection empowering researchers, clinicians, and patients to realize the promise of proteomics.
the future of healthcare and wellness
Unlocking Proteomics with you: We are passionate about partnering. to drive adoption of cutting-edge diagnostics.
If you would like to pilot NAB-Sure™ in your laboratory, please email your contact details to firstname.lastname@example.org
Feng has spent the last decade researching and inventing new techniques in the field of molecular and immuno-diagnostics. Before joining Spear Bio, he was the Technology Development Fellow at the Wyss Institute for Biologically Inspired Engineering at Harvard University where he invented Spear Bio's core technology. Feng received his B.S. in Chemistry & M.Phil. in Biomedical Engineering from Hunan University and his Ph.D. in Chemical and Biomolecular Engineering from Hong Kong University of Science and Technology.
Peng is a Professor in the Department of Systems Biology at Harvard Medical School. He also serves as a Core Faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University, where he co-founded Ultivue. Peng obtained his Ph.D. degree in computer science and MS in molecular cancer biology from Duke University, and a BS in biochemistry and molecular biology from Peking University.
Sr. Director, Commercial Strategy and Business Development
Oliver has spent the last decade leading business development and product management teams developing new markets and launching cutting edge, technology-driven products. Oliver most recently led program and product management teams at Thermo Fisher Scientific. He has a BS in Biological Engineering from Cornell University and an MBA from Carnegie Mellon University.
Head of Product Development
Graeme is a molecular biologist who led the development of microbial sequencing technologies as CSO of Pathogenica, and commercialized multiplexed biomarker product lines as a Director at Firefly BioWorks, which was acquired by Abcam in 2015. Graeme’s postdoctoral training at MIT and Harvard Medical School focused on non-coding RNA biology, and he holds an MBiochem in Biochemistry and DPhil in Human Genetics from Oxford University
Head of Application Development (Acting)
Yu comes to Spear Bio after spending three years as a Research Fellow at the Wyss Institute for Biologically Inspired Engineering at Harvard University. At Wyss, Yu collaborated closely with Spear Bio co-founders Feng Xuan and Peng Yin on validating and applying Spear Bio’s core technology. Prior to joining Spear Bio and his tenure at the Wyss Institute, Yu obtained his PhD in Biological and Biomedical Science from Harvard Medical School and received undergraduate biology degrees from Nanjing University and the University of Southampton.